Oncolytics Biotech (NASDAQ:ONCY) Announces Earnings Results, Beats Estimates By $0.01 EPS

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) posted its earnings results on Friday. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01, Zacks reports.

Oncolytics Biotech Stock Performance

Shares of Oncolytics Biotech stock traded down $0.03 during trading hours on Tuesday, reaching $0.61. The company's stock had a trading volume of 685,790 shares, compared to its average volume of 1,362,215. Oncolytics Biotech has a one year low of $0.58 and a one year high of $1.53. The company's 50 day simple moving average is $0.77 and its 200 day simple moving average is $0.93. The stock has a market cap of $52.38 million, a P/E ratio of -2.27 and a beta of 1.18.

Analyst Upgrades and Downgrades

ONCY has been the topic of a number of analyst reports. Raymond James raised Oncolytics Biotech to a "moderate buy" rating in a research report on Thursday, November 14th. Royal Bank of Canada dropped their price target on shares of Oncolytics Biotech from $6.00 to $5.00 and set an "outperform" rating for the company in a research note on Monday. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price target on shares of Oncolytics Biotech in a report on Monday. Maxim Group decreased their price objective on shares of Oncolytics Biotech from $5.00 to $3.00 and set a "buy" rating for the company in a report on Monday. Finally, Leede Financial lowered shares of Oncolytics Biotech from a "strong-buy" rating to a "moderate buy" rating in a research note on Wednesday, November 13th. Three equities research analysts have rated the stock with a buy rating, According to MarketBeat, Oncolytics Biotech presently has a consensus rating of "Buy" and an average price target of $4.00.

Remove Ads

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.